衍生中性粒细胞与淋巴细胞比值可预测乳腺癌新辅助化疗后的病理完全缓解情况。
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
作者信息
Ocaña Alberto, Chacón Jose Ignacio, Calvo Lourdes, Antón Antonio, Mansutti Mauro, Albanell Joan, Martínez María Teresa, Lahuerta Ainhara, Bisagni Giancarlo, Bermejo Begoña, Semiglazov Vladimir, Thill Marc, Chan Arlene, Morales Serafin, Herranz Jesús, Tusquets Ignacio, Chiesa Massimo, Caballero Rosalía, Valagussa Pinuccia, Bianchini Giampaolo, Alba Emilio, Gianni Luca
机构信息
Hospital Clínico San Carlos, Madrid e Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid and Universidad de Castilla La Mancha, Albacete, Spain.
Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
出版信息
Front Oncol. 2022 Feb 11;11:827625. doi: 10.3389/fonc.2021.827625. eCollection 2021.
BACKGROUND
Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT).
METHODS
This is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/-carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR.
RESULTS
In total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25-2.04) and at EOT 1.53 (IQR: 0.96-2.22). Baseline dNLR showed positive correlation with increased tumor size (-value = 1e-04). High baseline dNLR, as continuous variable or using median cutoff, was associated with lower likelihood of pCR in univariate analysis. High EOT dNLR as continuous variable or using quartiles was also associated with lower pCR rate in uni- and multivariate analyses.
CONCLUSIONS
High baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC.
背景
衍生中性粒细胞与淋巴细胞比值（dNLR）是一种与乳腺癌（BC）临床结局相关的生物标志物。我们分析了接受新辅助化疗（CT）的三阴性乳腺癌（TNBC）患者中dNLR与病理完全缓解（pCR）的相关性。
方法
这是一项对两项随机研究的回顾性分析，研究对象为接受蒽环类/紫杉类为基础的CT±卡铂（GEICAM/2006 - 03）或纳武单抗紫杉醇/紫杉醇后接蒽环类方案（ETNA）的早期/局部晚期TNBC患者。dNLR计算为CT前（基线）和治疗结束时（EOT）外周血中性粒细胞与总白细胞和中性粒细胞差值的比值。采用逻辑回归分析探讨dNLR与pCR的相关性。
结果
共分析了308例TNBC患者，其中216例来自ETNA，92例来自GEICAM/2006 - 03。基线时dNLR中位数为1.61（四分位间距（IQR）：1.25 - 2.04），EOT时为1.53（IQR：0.96 - 2.22）。基线dNLR与肿瘤大小增加呈正相关（-值 = 1e - 04）。在单因素分析中，高基线dNLR作为连续变量或使用中位数截断值，与pCR可能性较低相关。高EOT dNLR作为连续变量或使用四分位数，在单因素和多因素分析中也与较低的pCR率相关。
结论
高基线和EOT dNLR与TNBC新辅助CT获益较低相关。
Zotero 插件